Abstract:Congenital pseudarthrosis of the tibia (CPT, HP:0009736), commonly known as bowing of the tibia, is a rare congenital tibia malformation characterized by spontaneous tibial fractures and the difficulty of reunion after tibial fractures during early childhood, with a very low prevalence between 1/250,000∼1/140,000. While 80%–84% of CPT cases present with neurofibromatosis type 1, caused by the mutations in NF1 , the underlying cause of CPT is still unclear. Considering the congenital nature and the low prevalence of CPT, we hypothesized that the rare genomic mutations may contribute to CPT. In this study, we conducted whole exome sequencing on 159 patients with CPT and full-length transcriptome sequencing on an additional 3 patients with CPT. The data analysis showed there were 179 significantly up-regulated genes which were enriched in 40 biological processes among which 21 biological processes hold their loss of function (LoF) excesses between 159 cases against 208 controls from 1000 Genomes Project. From those 21 biological processes with LoF excesses, there were 259 LoF-carried genes among which 40 genes with 56 LoF variations in 63 patients were enriched in osteoclast differentiation pathway (hsa04380) with its 3 directly regulated pathways including MAPK signaling pathway (hsa04010), calcium signaling pathway (hsa04020) and PI3K-Akt signaling pathway (hsa04151), as well as fluid shear stress and atherosclerosis pathway (hsa05418) while 12 patients carried 9 LoF variations in the NF1 gene. The rare LoF variations in these pathways accounted for ∼39.6% of this CPT cohort. These findings shed light on the novel genetic mutations and molecular pathways involved in CPT, providing a new framework for understanding how the genetic variations regulate the biological processes in the pathology of CPT and indicating potential next directions to further elucidate the pathogenesis of CPT. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement Opening fundings of Hunan Provincial Key Laboratory of Pediatric Orthopedics ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Ethics committee/IRB of Hunan Children's Hospital gave ethical approval for this work I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes All data produced in the present study are available upon reasonable request to the authors <https://pan.genomics.cn/ucdisk/s/N73UJ3>

Additional File 4: of Identification and Characterization of NF1 and Non-Nf1 Congenital Pseudarthrosis of the Tibia Based on Germline NF1 Variants: Genetic and Clinical Analysis of 75 Patients

Additional File 5: of Identification and Characterization of NF1 and Non-Nf1 Congenital Pseudarthrosis of the Tibia Based on Germline NF1 Variants: Genetic and Clinical Analysis of 75 Patients

Identification and Characterization of NF1 and Non-Nf1 Congenital Pseudarthrosis of the Tibia Based on Germline NF1 Variants: Genetic and Clinical Analysis of 75 Patients

Identification of One <em>BOCR</em> Mutation and Five <em>NF1</em> Mutations in Male Patients with Neurofibromatosis Type 1 and Congenital Pseudarthrosis of the Tibia

Case Series of Congenital Pseudarthrosis of the Tibia Unfulfilling Neurofibromatosis Type 1 Diagnosis: 21% with Somatic NF1 Haploinsufficiency in the Periosteum.

Peroneal Myoatrophy Type 4H FGD4 New Gene Mutation in One Case and Literature Review

[The clinical characteristics of 497 children with congenital pseudarthrosis of the tibia]

Unraveling the Molecular Landscape of Congenital Pseudoarthrosis of the Tibia: Insights from a Comprehensive Analysis of 162 Probands

Genetic Analysis and Prenatal Diagnosis of a Sporadic Family with Neurofibromatosis Type 1

Clinical and Molecular Characteristics of Thirty NF1 Variants in Chinese Patients with Neurofibromatosis Type 1

Additional File 3 of Characterization of Novel CTNNB1 Mutation in Craniopharyngioma by Whole-Genome Sequencing

Case report and literature review: Novel compound heterozygous <i>FIG4</i> variants causing both of peripheral and central nervous system defects

A Novel TFG C.793c>g Mutation in a Chinese Pedigree with Charcot‐Marie‐Tooth Disease 2

Molecular Characterization of NF1 and Neurofibromatosis Type 1 Genotype-Phenotype Correlations in a Chinese Population

Genotype and phenotype analysis of two monozygotic twins with neurofibromatosis type 1 but inconsistent congenital pseudarthrosis

Case Report and Literature Review: Novel Compound Heterozygous FIG4 Variants Causing Both of Peripheral and Central Nervous System Defects

Identification of a Germline CSPG4 Variation in a Family with Neurofibromatosis Type 1-Like Phenotype

Identification of 11 Potentially Relevant Gene Mutations Involved in Growth Retardation, Intellectual Disability, Joint Contracture, and Hepatopathy

Clinical and Molecular Characterization of NF1 Patients

The Investigation for Potential Modifier Genes in Patients with Neurofibromatosis Type 1 Based on Next-Generation Sequencing

Clinical features and pedigree report of a patient with giant neurofibroma